aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
3.240
-0.040 (-1.22%)
At close: May 12, 2025, 4:00 PM
3.250
+0.010 (0.31%)
Pre-market: May 13, 2025, 8:17 AM EDT
aTyr Pharma Revenue
In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$235.00K
Revenue Growth
-33.43%
P/S Ratio
n/a
Revenue / Employee
$3,615
Employees
65
Market Cap
287.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
Dec 31, 2022 | 10.39M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATYR News
- 5 days ago - aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 5 weeks ago - aTyr Pharma to Participate in April Investor Conferences - GlobeNewsWire
- 6 weeks ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewsWire
- 2 months ago - aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
- 2 months ago - aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - GlobeNewsWire